1,027 material Form 8-K filings that 835 companies we cover made with the SEC in February 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
ESCO reported fiscal first-quarter 2025 sales of $247.0 million, up 13.2%, and GAAP EPS of $0.91 versus $0.59 a year earlier. The company raised its full-year fiscal 2025 adjusted EPS guidance to $5.55 to $5.75 from $5.30 to $5.50, though it now excludes acquisition-related amortization from adjusted EPS. The filing also covered the annual meeting, where directors and executive pay were approved, and a board reduction from nine to eight directors.
Q1 fiscal 2025 sales were $247.0 million, up from $218.3 million; GAAP EPS was $0.91 versus $0.59.
Adjusted EPS excluding acquisition-related amortization was $1.07, up 41% from $0.76 a year earlier.
Full-year fiscal 2025 adjusted EPS guidance raised by $0.25 to $5.55 to $5.75; Q2 adjusted EPS guidance is $1.20 to $1.30.
Pending $550 million SM&P acquisition; US closing conditions met, UK review in final stages. Board size cut to eight after Leon J. Olivier retired.
QuinStreet reported record fiscal second quarter 2025 revenue of $282.6 million for the quarter ended December 31, 2024, up 130% year-over-year, and posted a GAAP net loss of $1.5 million, or $0.03 per diluted share. The company raised its full fiscal 2025 outlook, now expecting revenue of $1.065 billion to $1.105 billion and Adjusted EBITDA of $80 million to $85 million.
Q2 revenue was $282.6 million, up 130% year-over-year, with Auto Insurance revenue up 615% and non-insurance revenue up 15%.
GAAP net loss narrowed to $1.5 million, or $0.03 per diluted share, from a net loss of $11.6 million a year earlier; adjusted net income was $11.9 million, or $0.20 per diluted share.
Adjusted EBITDA was $19.4 million for the quarter, compared with $417 thousand a year earlier.
For fiscal Q3, the company expects revenue of $265 million to $275 million and Adjusted EBITDA of $19.5 million to $20.0 million.
For the quarter ended December 31, 2024, e.l.f. Beauty reported net sales up 31% to $355.3 million, but GAAP diluted earnings per share fell to $0.30 from $0.46 a year earlier. The company lowered its fiscal 2025 outlook, with net sales now expected at $1,300-1,310 million versus the prior $1,315-1,335 million, and it cited softer than expected trends in January.
Q3 net sales rose 31% to $355.3 million; GAAP net income was $17.3 million versus $26.9 million a year earlier.
Q3 GAAP diluted EPS was $0.30 versus $0.46; adjusted diluted EPS was $0.74, flat with the prior year.
Fiscal 2025 net sales outlook cut to $1,300-1,310 million from $1,315-1,335 million; adjusted EBITDA outlook cut to $289-293 million from $304-308 million.
CFO Mandy Fields said the company is taking a prudent approach to the final fiscal quarter given softer January trends.
CMS Energy reported full-year 2024 diluted EPS of $3.33, up from $3.01, and adjusted EPS of $3.34, up from $3.11. It raised its 2025 adjusted EPS guidance to $3.54 to $3.60 from $3.52 to $3.58 and increased its annual dividend by 11 cents to $2.17 per share. Fourth-quarter results were lower than a year earlier, with diluted EPS of $0.87 compared with $1.05.
Full-year 2024 operating revenue was $7.5 billion ($7,515 million) versus $7.5 billion ($7,462 million) in 2023, and net income available to common stockholders was $993 million versus $877 million.
Fourth-quarter 2024 net income available to common stockholders was $262 million, down from $306 million in the fourth quarter of 2023.
2025 adjusted EPS guidance was raised to $3.54 to $3.60 from $3.52 to $3.58 per share, and long-term adjusted EPS growth of 6 to 8 percent was reaffirmed.
The company's 2025 annual dividend is $2.17 per share, up 11 cents, its 19th consecutive annual increase.
Haemonetics reported third-quarter fiscal 2025 revenue of $348.5 million, up 3.7%, and GAAP earnings of $0.74 per diluted share, up from $0.61. The company lowered its fiscal 2025 reported revenue growth guidance to 3% to 5% from 5% to 8% and cut free cash flow guidance to $120 million to $140 million from $130 million to $180 million, while narrowing its adjusted earnings per share guidance to $4.50 to $4.70.
Third-quarter revenue was $348.5 million, up 3.7%, while organic revenue decreased 0.3%.
GAAP earnings per diluted share were $0.74, versus $0.61 a year earlier; adjusted earnings per diluted share were $1.19, up 14.4%.
Fiscal 2025 reported revenue growth guidance was lowered to 3% to 5% from 5% to 8%.
Free cash flow guidance was cut to $120 million to $140 million from $130 million to $180 million; adjusted earnings per share guidance was narrowed to $4.50 to $4.70 from $4.45 to $4.75.
Prestige Consumer Healthcare reported third-quarter fiscal 2025 revenue of $290.3 million, up 2.7%, with diluted EPS of $1.22 versus $1.06 a year earlier. The company raised its fiscal 2025 adjusted diluted EPS outlook to approximately $4.50 from $4.40 to $4.46, and narrowed its revenue outlook to $1,128 million to $1,132 million. Nine-month revenue declined 0.8%, and third-quarter free cash flow fell, so shareholders gain from higher earnings guidance but see mixed trends in sales and cash flow.
Q3 revenue $290.3 million, up 2.7% from $282.7 million; diluted EPS $1.22 versus $1.06
Nine-month revenue $841.2 million, down 0.8%; non-GAAP adjusted diluted EPS $3.20 versus $3.19
FY2025 adjusted diluted EPS outlook raised to approximately $4.50 from $4.40 to $4.46; revenue outlook $1,128 million to $1,132 million
Q3 non-GAAP free cash flow $63.5 million versus $69.5 million; net debt about $0.9 billion, leverage 2.5x
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.